Challenges for cancer vaccine development

Challenges for cancer vaccine development

The first generation of human cancer vaccines has been tested in phase III clinical trials, but only a few of these have demonstrated sufficient efficacy to be licensed for clinical use. This article reviews some of the mechanisms that could contribute to these limited clinical responses, and highli...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advanced drug delivery reviews 2006-10, Vol.58 (8), p.902-915
Hauptverfasser: Tabi, Z., Man, S.
Format: Artikel
Sprache:eng
Schlagworte:
Animals
Antigens, Neoplasm - immunology
Cancer Vaccines - adverse effects
Cancer Vaccines - therapeutic use
Humans
Immune evasion
Immunosuppression
Immunotherapy
Neoplasms - immunology
Neoplasms - therapy
Tumour vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The first generation of human cancer vaccines has been tested in phase III clinical trials, but only a few of these have demonstrated sufficient efficacy to be licensed for clinical use. This article reviews some of the mechanisms that could contribute to these limited clinical responses, and highlights the challenges faced for development of future vaccines.
ISSN:0169-409X
1872-8294
DOI:10.1016/j.addr.2006.05.004